On September 17, 2020 the Mayo Clinic Proceedings published a comprehensive analysis of the role of omega-3 on cardiovascular risk prevention. The analysis offers a detailed review of 40 prior clinical trials, and provides authoritative evidence to support the consumption of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid).
The analysis concludes that EPA and DHA intake from omega 3 supplements is associated with reduced risk of coronary heart disease (CHD) events, which is known to be the cause of more than 7 million deaths around the world each year. Additionally, the study concludes that EPA and DHA consumption reduces the risk of myocardial infarction (heart attack), including fatal heart attacks.
REDUCED RISK TABLE:
Fatal heart attack (35 percent reduction)
Non-fatal heart attack (13 percent reduction)
CHD events and mortality (9-10 percent reduction)
The study supports the notion that EPA and DHA intake contributes to cardioprotection, and that whatever patients are getting through the diet, they likely need more, as cardiovascular benefits appear to increase along with EPA/DHA dosage. Study results showed that subjects decreased the risk of cardiovascular disease and heart attack by supplementing an additional 1000 mg of EPA and DHA each day.
EPA and DHA omega-3 fatty acids are long-chain, marine-based polyunsaturated fatty acids. Consumption of fatty fish such as salmon, anchovies and sardines, is the direct way to get EPA and DHA omega-3s into your diet. However, most people around the world and in the United States consume less than the recommended amount of fish. Omega 3 supplementation can reduce or eliminate that deficiency.
“People should consider the benefits of omega-3 supplements, at doses of 1000 to 2000 mg per day – far higher than what is typical, even among people who regularly eat fish,” added study author Dr. Carl Lavie. “Given the safety and diminished potential for interaction with other medications, the positive results of this study strongly suggest omega-3 supplements are a relatively low-cost, high impact way to improve heart health with few associated risks and should be considered as part of a standard preventive treatment for most patients with cardiovascular diseases and those recovering from myocardial infarction.”
The entire study, inclduing its conclusions, risks, methodologies, limitations, and all other data is linked below.
Reference: “Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis and Meta-Regression of Interventional Trials” by Aldo A. Bernasconi, PhD; Michelle M. Wiest, PhD; Carl J. Lavie, MD; Richard V. Milani, MD; and Jari A. Laukkanen, MD, PhD, 17 September 2020, Mayo Clinic Proceedings.
*These statements have not been evaluated by the Food and Drug Administration.